Osteoprotegerin, Parathyroid Hormone and Vitamin D as Effective Factors on Serum-Urine Calcium Levels in Breast Cancer Patients

Document Type : Original Articles

Authors

1 College of Pharmacy, AL-Zahraa University for Women, Kerbala, Iraq

2 College of Science, Department of Chemistry, AL-Mustansiriyah University, Baghdad, Iraq

Abstract

Breast cancer represents one of the most popular kinds of cancer worldwide. During the early stages of the disease, the level of Osteoprotegerin remained within normal limits, showing that the bone was not being damaged to get calcium due to an increase in parathyroid hormone. The current study aimed to assess a number of biochemical variables in a group of women with malignant breast cancer who had reached menopause (less than 45 years old). One hundred thirty women were randomly divided into three groups as follows. The first group (G1) is made up of women who have never had breast cancer or any other disease, and their number (40) corresponds to the same age range (below menopause) as the control group. The second group (G2) comprises women diagnosed with breast cancer at an early stage whose numbers were relatively low (45). The third group (G3) included women of the same age who received one or two doses of chemotherapy and whose total number was (45) over the same period. The variables studied include Vitamin D, Parathyroid Hormone, Osteoprotegerin, blood calcium, and urine calcium, all of that are thought to play a role in the progress of the disease. Vitamin D levels were extremely low in the second group (G2), while they were slightly higher in the third group (G3) but remained extremely low. The first group (G1) maintained parameters within acceptable limits. There was a significant difference between the two breast cancer groups (9.38 1.43) and (4.98 1.67) when compared to the control group (20.04 2.80). (G1). The two breast cancer groups (G2) and (G3) had higher parathyroid hormone levels than the control group (G1), and there was a significant difference between the two breast cancer groups (136.52 58.56) (G3) and (G2) (167.79 35.21) compared to the control group (68.52 20.44) (G1). There was no significant difference in Osteoprotegerin levels between the two breast cancer groups (313.38 109.02) (G3) and (315.0 123.98) (G2) compared to the control group (G1) (324.11 104.73). The three groups' blood calcium levels were all within normal ranges, and there was no statistically significant difference between them (9.21 0.45), (9.23 0.38), and (9.23 0.38) (G3) (9.28 0.43). (G1), but urine-calcium levels were lower in both groups of breast cancer patients compared to the control group, and there was a significant difference between the two breast cancer groups (63.96 15.66) (G3) and (68.42 14.05) (G2) compared to the control group (213.77 63.94) (G1). In breast cancer patients, vitamin D deficiency and high parathyroid hormone levels were discovered, suggesting that vitamin D may play a role in cancer prevention. Osteoprotegerin levels were within normal ranges early in the illness, although this may alter as the patient matures and the disease advances.

Keywords

References

  1. Mohammad WA, Ebrahim AA-E. Reconstruction of chest wall defects after cardiac surgery. Al-Azhar Assiut Med J. 2015;13(4):2.
  2. Steyna K. Conceptual framework. View a breakdown of smaller files at http://www mrc ac za/chronic/cdl1995-2005 htm. 2006:1.
  3. Hadj-Ahmed M, Ghali RM, Bouaziz H, Habel A, Stayoussef M, Ayedi M, et al. Transforming growth factor beta 1 polymorphisms and haplotypes associated with breast cancer susceptibility: A case-control study in Tunisian women. Tumor Biol. 2019;41(8):1010428319869096.
  4. Brayboy LM, Oulhen N, Long S, Voigt N, Raker C, Wessel GM. Multidrug resistance transporter-1 and breast cancer resistance protein protect against ovarian toxicity, and are essential in ovarian physiology. Reprod Toxicol. 2017;69:121-31.
  5. Nsaif GS, Abdallah AH, Ahmed NS, Alfatlawi WR. Evaluation of estridiol and some antioxidant in breast cancer iraqi women. Al-Nahrain J Sci. 2018;21(1):35-40.
  6. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res. 2015;149(3):569-75.
  7. Puliti D, Duffy SW, Miccinesi G, De Koning H, Lynge E, Zappa M, et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012;19(1):42-56.
  8. Sergeev I. Calcium as a mediator of 1, 25-dihydroxyvitamin D3-induced apoptosis. J Steroid Biochem Mol Biol. 2004;89:419-25.
  9. Russo J, Russo IH. The pathway of neoplastic transformation of human breast epithelial cells. Radiat Res. 2001;155(1):151-4.
  10. Lipkin M, Kelloff G, Newmark HL. Calcium, vitamin D, and prevention of colon cancer: CRC Press Boca Raton; 1991.
  11. Wang D, Weng Y, Guo S, Zhang Y, Zhou T, Zhang M, et al. Platelet-rich plasma inhibits RANKL-induced osteoclast differentiation through activation of Wnt pathway during bone remodeling. Int J Mol Med. 2018;41(2):729-38.
  12. Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145-58.
  13. Lanske B, Razzaque MS. Molecular interactions of FGF23 and PTH in phosphate regulation. Kidney Int. 2014;86(6):1072-4.
  14. Brown EM. Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best Pract Res Clin Endocrinol Metab. 2013;27(3):333-43.
  15. Bisello A, Friedman PA. PTH and PTHrP actions on kidney and bone. Principles Bone Biol. 2008:665-712.
  16. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342-57.
  17. Boettger SF, Angersbach B, Klimek CN, Wanderley ALM, Shaibekov A, Sieske L, et al. Prevalence and predictors of vitamin D-deficiency in frail older hospitalized patients. BMC Geriatr. 2018;18(1):1-6.
  18. Sofi NY, Jain M, Kapil U, Seenu V, Kamal VK, Pandey RM. Nutritional risk factors and status of serum 25 (OH) D levels in patients with breast cancer: A case control study in India. J Steroid Biochem Mol Biol. 2018;175:55-9.
  19. Johnson AL, Zinser GM, Waltz SE. Loss of vitamin D receptor signaling from the mammary epithelium or adipose tissue alters pubertal glandular development. Am J Physiol Endocrinol Metab. 2014;307(8):674-85.
  20. Gjorevski N, Nelson CM. Integrated morphodynamic signalling of the mammary gland. Nat Rev Mol Cell Biol. 2011;12(9):581-93.
  21. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology. 2010;151(1):32-42.
  22. Kerdivel G, Flouriot G, Pakdel F. Modulation of estrogen receptor alpha activity and expression during breast cancer progression. Vitam Horm. 2013;93:135-60.
  23. Tosovic A, Becker C, Bondeson AG, Bondeson L, Ericsson UB, Malm J, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. Int J Cancer. 2012;131(9):2126-33.
  24. Martin TJ, Johnson RW. Multiple actions of parathyroid hormone‐related protein in breast cancer bone metastasis. Br J Pharmacol. 2021;178(9):1923-35.
  25. Angelousi AG, Anagnostou VK, Stamatakos MK, Georgiopoulos GA, Kontzoglou KC. Primary HT and risk for breast cancer: a systematic review and meta-analysis. Eur J Endocrinol. 2012;166:373-81.
  26. Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 2015;16(2):165-74.
  27. Meehan AD, Udumyan R, Kardell M, Landén M, Järhult J, Wallin G. Lithium-associated hypercalcemia: pathophysiology, prevalence, management. World J Surg. 2018;42(2):415-24.
  28. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol. 2015;10(7):1257-72.
  29. Goswami S, Sharma-Walia N. Osteoprotegerin rich tumor microenvironment: implications in breast cancer. Oncotarget. 2016;7(27):42777.
  30. Sisay M, Mengistu G, Edessa D. The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. Onco Targets Ther. 2017;10:3801.
  31. Pettersen I, Bakkelund W, SMEDSRØD B, Sveinbjørnsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005;25(6):3809-16.
  32. VanHouten JN. Calcium sensing by the mammary gland. J Mammary Gland Biol Neoplasi. 2005;10(2):129-39.
  33. Mathiasen IS, Sergeev IN, Bastholm L, Elling F, Norman AW, Jäättelä M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J Biol Chem. 2002;277(34):30738-45.
  34. McCullough ML, Rodriguez C, Diver WR, Feigelson HS, Stevens VL, Thun MJ, et al. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2898-904.
  35. Larijani B, Hossein-Nezhad A, Feizabad E, Maghbooli Z, Adibi H, Ramezani M, et al. Vitamin D deficiency, bone turnover markers and causative factors among adolescents: a cross-sectional study. J Diabetes Metab Disord. 2016;15(1):1-6.
  36. Heaney R. Toward a physiological referent for the vitamin D requirement. J Endocrinol Invest. 2014;37(11):1127-30.
  37. Cheng I, Klingensmith ME, Chattopadhyay N, Kifor O, Butters RR, Soybel DI, et al. Identification and localization of the extracellular calcium-sensing receptor in human breast. J Clin Endocrinol Metab. 1998;83(2):703-7.
  38. Mihai R, Stevens J, McKinney C, Ibrahim N. Expression of the calcium receptor in human breast cancer—a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol. 2006;32(5):511-5.
  39. Liu G, Hu X, Chakrabarty S. Calcium sensing receptor down-regulates malignant cell behavior and promotes chemosensitivity in human breast cancer cells. Cell Calcium. 2009;45(3):216-25.
  40. Cui Y, Vogt S, Olson N, Glass AG, Rohan TE. Levels of zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1682-5.
  41. Journé F, Dumon J-C, Kheddoumi N, Fox J, Laı̈os I, Leclercq G, et al. Extracellular calcium downregulates estrogen receptor alpha and increases its transcriptional activity through calcium-sensing receptor in breast cancer cells. Bone. 2004;35(2):479-88.
  42. Bérubé S, Diorio C, Mâsse B, Hébert-Croteau N, Byrne C, Côté G, et al. Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomark Prev. 2005;14(7):1653-9.
  43. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005;6(10):798-808.
  1. Bérubé S, Diorio C, Verhoek-Oftedahl W, Brisson J. Vitamin D, calcium, and mammographic breast densities. Cancer Epidemiol Biomark Prev. 2004;13(9):1466-72.
  2. Masala G, Ambrogetti D, Assedi M, Giorgi D, Del Turco MR, Palli D. Dietary and lifestyle determinants of mammographic breast density. A longitudinal study in a Mediterranean population. Int J cancer. 2006;118(7):1782-9.
Archives of Razi Institute
Volume 77, Issue 5 - Serial Number 5
September and October 2022
Pages 1975-1986

Files

Share

How to cite

Statistics